ADVANCE: Breaking new ground in type 2 diabetes

Journal of Hypertension

Volumn 24, Issue SUPPL. 5, 2006, Pages

  Chalmers, John ^a,b   Perkovic, Vlado ^a   Joshi, Rohina ^a   Patel, Anushka ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Blood pressure lowering; Diamicron MR; Intensive glucose control; Macrovascular disease; Microvascular disease; Perindoprilindapamide combination; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO; PRETERAX; SULFONYLUREA; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; TABLET; TREATMENT OUTCOME;

EID: 33748045173     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000240043.50838.28     Document Type: Article

References (33)

1. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - Preterax and Diamicron MR controlled evaluation. Diabetologia 2001; 44:1118-1120.
2. ADVANCE Collaborative Group. Rationale and Design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes mellitus. J Hypertens 2001; 19 (Suppl. 4):S21-S28.
3. ADVANCE Collaborative Group. ADVANCE action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2005; 22:882-888.
4. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
6. Lievre M, Gueyffier F, Ekbom T, Fagard R, Cutler J, Schron E, et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. Diabetes Care 2000; 23 (Suppl. 2):B65-B71.
7. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157:181-188.
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
10. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
12. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421-431.
13. Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004; 27:2836-2842.
14. 1999 World Health Organization/International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
15. 2003 World Health Organisation (WHO)/International Society of Hypertension (ISH). Statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
16. Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
17. The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: JNC VII EXPRESS. JAMA 2003; 289:2560-2572.
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
19. Patel A, Joshi R, Colman S, Chalmers J, Neal B, MacMahon S. Effects of low dose perindopril-indapamide combination on blood pressure in type 2 diabetes: the ADVANCE trial run-in phase. J Hypertens 2005; 23 (Suppl. 2):S212-S213.
20. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004; 22:2379-2386.
21. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41:1063-1071.
22. Renaud IM, Chainey A, Belair MF, Mandet C, Michel O, Myara I, et al. Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination. Fundam Clin Pharmacol 2004; 18:437-447.
23. Rakusan K, Cicutti N, Maurin A, Guez D, Schiavi P. The effect of treatment with low dose ACE Inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res 2000; 59:243-254.
24. Levy BI, Duriez M, Samuel JL. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 2001; 14:7-13.
25. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001; 104:735-740.
26. Mourad JJ, Hanon O, Deverre JR, Camici PG, Sellier P, Duboc D, Safar ME. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotens Aldoster Syst 2003; 4:94-95.
27. Dahlöf B, Gosse P, Gueret P, Dubourg O, de Simone G, SChmieder R, et al. The PICXEL Study: benefits of preterax on LVH reduction. J Hypertens 2004; 22 (Suppl. 2):S410.
28. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflection with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with artenolol. Hypertension 2001; 38:922-926.
29. Safar ME, Levy BI, Struijker-Boudler H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107:2864-2869.
30. Safar ME. Peripheral pulse pressure, large arteries and microvessels. Hypertension 2004; 44:121-122.
31. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction of a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43:92-99.
32. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE Study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34:535-542.
33. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.